China Universal Asset Management Co., Ltd. Graphite Bio, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$2.18 - $2.77 $1,576 - $2,002	723 Added 95.01%	1,484 $3,000
Q3 2023 Oct 30, 2023	BUY	$2.18 - $2.77 $1,576 - $2,002	723 Added 95.01%	1,484 $4,000
Q2 2023 May 21, 2024	SELL	$2.47 - $3.38 $66 - $91	-27 Reduced 3.43%	761 $1,000
Q2 2023 Jul 27, 2023	SELL	$2.47 - $3.38 $66 - $91	-27 Reduced 3.43%	761 $2,000
Q1 2023 May 21, 2024	BUY	$1.85 - $3.21 $364 - $632	197 Added 33.33%	788 $1,000
Q1 2023 Apr 27, 2023	BUY	$1.85 - $3.21 $364 - $632	197 Added 33.33%	788 $2,000
Q4 2022 May 21, 2024	BUY	$2.82 - $3.59 $1,666 - $2,121	591 New	591 $1,000
Q4 2022 Jan 31, 2023	BUY	$2.82 - $3.59 $126 - $161	45 Added 8.24%	591 $2,000
Q3 2022 Oct 21, 2022	BUY	$2.82 - $4.24 $1,539 - $2,315	546 New	546 $2,000

Others Institutions Holding GRPH

# of Institutions

Shares Held

637K

Call Options Held

Put Options Held

View Full List

About Graphite Bio, Inc.

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

More about GRPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account